Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with <i>VHL</i>-deficiency allows for selective targeting of clear cell renal cell carcinoma.

Only a few mice had high amounts of human transcripts in the lungs, all being from the Vehicle-treated group; the averaged data showed a tendency for lower metastatic burden in Dinaciclib-treated mice but did not reach statistical significance (Supplementary Figure 5(a)).

also in 111,027 other papers